​BioCryst Pharmaceuticals Inc., maker of the flu drug Rapivab, announced Monday that the European Medicines Agency will review its drug for the treatment of flu symptoms in adults.

The London-based overseer of drugs sold in the European Union will issue a decision within 210 days on whether to allow the sale of Rapivab in the EU’s 28 member states and Norway and Iceland, a market of more than 500 million consumers.

In December 2014, the U.S. Food and Drug Administration approved BioCryst’s Rapivab — an injection also known as peramivir — to treat influenza in adults. The drug is also approved in Japan and Korea. Its efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

Seqirus, a supplier of influenza vaccines to global markets, will sell the drug in Europe, BioCryst said. In June 2015, BioCryst entered into a license agreement with Seqirus to manufacture and commercialize Rapivab for the treatment of influenza worldwide, except in Israel, Japan, Korea and Taiwan.

“This filing brings BioCryst and Seqirus one step closer to making the only single-dose, I.V. influenza therapy available to an important market, the European Union,” said Jon Stonehouse, BioCryst president and chief executive officer.

Founded in 1986, BioCryst has approximately 68 employees between the company’s headquarters in Research Triangle Park, North Carolina, and its Discovery Center of Excellence in Birmingham, Alabama.

Apart from its only FDA-approved drug Rapivab, BioCryst is developing two more drugs: BCX7353 and BCX4430. The company in Phase 2 of approval for its drug BCX7353 to treat an inherited blood disorder that causes swelling attacks.

The company is in Phase 1 of approval for BCX4430 to treat a group of infectious diseases, including Ebola and Zika. BioCryst has a $39.5 million contract with the National Institute of Allergy and Infectious Diseases to develop this drug.

NC Biz News reported in September that BioCryst announced positive study results for BCX4430.

BioCryst trades on the NASDAQ under the ticker BCRX. Shares were trading around $6.04 Monday morning, down 6.36 percent. This month’s low was Jan. 23 at $5.92 compared with a high of $7.13 on Jan. 6.

Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism